1205.9000 11.20 (0.94%)
NSE Sep 19, 2025 15:31 PM
Volume: 62,857
 

1205.90
0.94%
ICICI Securities Limited
Thyrocare Technologies’ (Thyrocare) core business grew 18% YoY in Q4FY24 driven by 13% YoY jump in sales from franchisee and 40% from partnerships (excluding API & B2G). EBITDA margin at 21.9% was weaker (I-Sec: 25.1%) as the company has
inched up investments in marketing and promotion for new bundled test programmes like Jaanch, Her Check and Troponin I and for other initiatives.
Thyrocare Technologies Ltd. is trading below its 30 day SMA of 1297.1
More from Thyrocare Technologies Ltd.
Recommended